MST-312 (Synonyms: Telomerase Inhibitor IX) |
Catalog No.GC18769
One-Click Copy Product Info
|
MST-312 is a potent telomerase inhibitor, with an IC50 value of 0.67μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 368449-04-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MST-312 is a potent telomerase inhibitor, with an IC50 value of 0.67μM [1]. MST-312 reduces the activity of telomerase in cells, causing telomere dysfunction, leading to DNA damage and cell growth arrest[2]. MST-312 has been widely used to inhibit the proliferation of leukemia cells, and new combined therapies have been developed to suppress the vitality of tumor cells[3].
In vitro, MST-312 treatment for 72 hours significantly inhibited the viability of PA-1 cells, A2780 cells and OVCAR3 cells, with IC50 values of 4.2μM, 3.9μM and 7.1μM, respectively[4]. Treatment with 8μM MST-312 for 48 hours reduced the cell viability and metabolic activity of U-266 cells and induced cell apoptosis[5]. Treatment with 4μM MST-312 for 48 hours inhibited the proliferation of Jurkat cells and downregulated the expressions of CCND1, MDM2, MYC and HSP90AA1[6]. Treatment with 100μM MST-312 for 18 hours inhibited the replication of HSV-1 virus in HEp-2 cells, reduced the number of cells exhibiting cytopathic effects, and decreased the accumulation of early and late viral proteins[7].
In vivo, MST-312 treatment via oral administration (400mg/kg; 5 times a week) for 6 weeks inhibited the growth of tumor volume in the HBC-4 cell-xenograft mouse model and caused weight loss in mice[8].
References:
[1] Seimiya H, Oh-hara T, Suzuki T, et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-199[J]. Molecular cancer therapeutics, 2002, 1(9): 657-665.
[2] Gurung R L, Lim S N, Low G K M, et al. MST-312 alters telomere dynamics, gene expression profiles and growth in human breast cancer cells[J]. Journal of Nutrigenetics and Nutrigenomics, 2015, 7(4-6): 283-298.
[3] Ghasemimehr N, Farsinejad A, Khalilabadi R M, et al. The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells[J]. Biomedicine & Pharmacotherapy, 2018, 106: 1742-1750.
[4] Fernandes S G, Gala K, Khattar E. Telomerase inhibitor MST-312 and quercetin synergistically inhibit cancer cell proliferation by promoting DNA damage[J]. Translational Oncology, 2023, 27: 101569.
[5] Ameri Z, Ghiasi S, Farsinejad A, et al. Telomerase inhibitor MST-312 induces apoptosis of multiple myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes[J]. Life Sciences, 2019, 228: 66-71.
[6] Bahmei A, Karimi F, Mahini S M, et al. Targeting telomerase with MST-312 leads to downregulation of CCND1, MDM2, MYC, and HSP90AA1 and induce apoptosis in Jurkat cell line[J]. Medical Oncology, 2024, 41(11): 267.
[7] Haberichter J, Roberts S, Abbasi I, et al. The telomerase inhibitor MST-312 interferes with multiple steps in the herpes simplex virus life cycle[J]. Journal of Virology, 2015, 89(19): 9804-9816.
[8] Fujiwara C, Muramatsu Y, Nishii M, et al. Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells[J]. Scientific reports, 2018, 8(1): 14827.
| Cell experiment [1]: | |
Cell lines | A2780 cells |
Preparation Method | A2780 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin 100U/ml, streptomycin 0.1mg/ml) under normal conditions (5% CO2 with 95% humidified air). A2780 cells (8×104 cells) were plated using 96-well plates and subjected to incubation for 24h in a 5% CO2 incubator. Incubation was followed by treatment with different doses of MST-312 (0.1, 1, 10, and 100μM) for 72h and cell viability was measured. |
Reaction Conditions | 0.1, 1, 10, and 100μM; 72h |
Applications | MST-312 treatment decreased the cell viability of A2780 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | BALB/cAJcl-nu nude mice |
Preparation Method | The HBC-4 cells were subcutaneously implanted into the right abdomen of 9-week-old BALB/cAJcl-nu nude mice. The experiment began when the tumor volume reached 50-150mm3 (on day 0). In the experimental group mice, MST-312 was administered at a dose of 400mg/kg, 5 times a week, once a day, for 6 weeks. The control group mice (n=6) received the same volume of normal saline as the experimental group mice (n=6). The tumor growth was monitored. The length (L) and width (W) of the tumor were measured, and the tumor volume (TV) was calculated using the formula TV=LW2/2. |
Dosage form | 400mg/kg; 5 times a week for 6 weeks; p.o. |
Applications | MST-312 treatment inhibited the growth of tumor volume in a HBC-4 cell-xenograft mouse model and caused weight loss in mice. |
References: | |
| Cas No. | 368449-04-1 | SDF | |
| Synonyms | Telomerase Inhibitor IX | ||
| Chemical Name | N,N'-1,3-phenylenebis[2,3-dihydroxy-benzamide | ||
| Canonical SMILES | OC1=C(O)C(C(NC2=CC=CC(NC(C3=C(O)C(O)=CC=C3)=O)=C2)=O)=CC=C1 | ||
| Formula | C20H16N2O6 | M.Wt | 380.4 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:40): 0.025 mg/ml,Ethanol: 0.2 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6288 mL | 13.1441 mL | 26.2881 mL |
| 5 mM | 525.8 μL | 2.6288 mL | 5.2576 mL |
| 10 mM | 262.9 μL | 1.3144 mL | 2.6288 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)